Bevacizumab & Glioblastoma multiforme (GBM) / Glioblastoma

Regulatory status

In the context of Bevacizumab & Glioblastoma multiforme (GBM) / Glioblastoma, the US FDA granted accelerated approval on May 5, 2009 for bevacizumab as a single‑agent treatment for adult patients with glioblastoma multiforme (GBM) that has progressed following prior therapy (i.e., recurrent GBM) (1, 2). The European Medicines Agency (EMA) has not approved bevacizumab for glioblastoma (3).

Clinical data

Two trials evaluating bevacizumab, 10 mg/kg by i.v. infusion every 2 weeks, revealed partial responses in 25.9% (95% confidence interval [CI], 17.0%–36.1%) of the patients. The median response duration was 4.2months (9…